Back to Search
JONATHAN KOLITZ, MD
MD
Hematology & Oncology Physician
NPI: 1770653115IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
144370(NY)
Education
YALE UNIVERSITY SCHOOL OF MEDICINE
Class of 1979
Research & Publications (20)
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621.
PMID 15514371·J Clin Oncol·2004
3-trial
Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
PMID 19451432·J Clin Oncol·2009
8-other
Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.
PMID 18809607·J Clin Oncol·2008
8-other
Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA.
PMID 18812466·Blood·2008
8-other
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.
PMID 18591543·J Clin Oncol·2008
3-trial
High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study.
PMID 18378853·Blood·2008
3-trial
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
PMID 18559874·J Clin Oncol·2008
8-other
MicroRNA expression in cytogenetically normal acute myeloid leukemia.
PMID 18450603·N Engl J Med·2008
8-other
FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.
PMID 17940205·Blood·2008
8-other
Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511.
PMID 17264295·Blood·2007
3-trial
Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study.
PMID 17341662·Blood·2007
8-other
High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.
PMID 17577018·J Clin Oncol·2007
8-other
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.
PMID 16921041·J Clin Oncol·2006
8-other
Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study.
PMID 16670265·Blood·2006
4-observational
A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse.
PMID 16730060·Leuk Res·2006
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- THE MONTER CANCER CENTER, 450 LAKEVILLE ROAD
LAKE SUCCESS, NY 11042 - Phone
- (516) 734-8970
Quick Facts
- NPI
- 1770653115
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 47
- Publications
- 20
Are you this provider?
Claim Your Profile